子宫内膜样子宫内膜癌错配修复蛋白缺陷免疫组化在子宫内膜活检/刮宫与子宫切除标本上的结果等效
研究对99例子宫内膜样子宫内膜癌患者配对的内膜活检/刮宫与子宫切除标本行错配修复蛋白(MLH1、MSH2、MSH6、PMS2)免疫组化,99例中91例活检/刮宫标本含癌、8例仅见复杂不典型增生,子宫切除标本均见癌;两标本间错配修复蛋白表达模式一致率为100%,69例保留全部四种蛋白、30例缺陷。
要点
- 99例配对标本中,内膜活检/刮宫与子宫切除标本的错配修复蛋白表达模式一致率为100%。
- 69例保留全部四种错配修复蛋白,30例缺陷:26例MLH1和PMS2缺陷、3例MSH2和MSH6缺陷、1例PMS2缺陷。
- 91例活检/刮宫标本含癌、8例仅见复杂不典型增生,而99例子宫切除标本均见癌。
核心结论
- 在子宫内膜癌林奇综合征筛查中,错配修复蛋白免疫组化可在内膜活检/刮宫或子宫切除标本上进行,准确率相同。
- 对诊断性内膜活检/刮宫进行常规检测可能更早发现错配修复蛋白缺陷,提高患者接受遗传咨询的比例,并可能更早识别免疫治疗候选者。
- 在无法行子宫切除的患者中,基于内膜活检/刮宫的可靠林奇综合征免疫组化筛查可指导患者管理和遗传咨询。
研究设计与样本
- 研究纳入99例诊断为子宫内膜样子宫内膜癌的患者,对其诊断性内膜活检/刮宫标本与配对的子宫切除标本行MLH1、MSH2、MSH6和PMS2免疫组化。
- 每份标本按错配修复蛋白保留或缺陷评分。
主要发现
- 99例内膜活检/刮宫标本中91例含癌,8例仅见复杂不典型增生;99例子宫切除标本均见癌。
- 按全部99例患者分析,内膜活检/刮宫与配对子宫切除标本间错配修复蛋白表达模式一致率为100%。
- 69例保留全部四种错配修复蛋白,30例错配修复蛋白缺陷,其中26例MLH1和PMS2缺陷、3例MSH2和MSH6缺陷、1例PMS2缺陷。
临床怎么用
- 作者认为,在子宫内膜癌林奇综合征筛查中,错配修复蛋白免疫组化在内膜活检/刮宫或子宫切除标本上均可执行且准确率相同。
- 作者认为,对诊断性内膜活检/刮宫行常规检测可能更早发现错配修复蛋白缺陷,改善患者遗传咨询的接受度,并可能更早识别免疫治疗候选者。
- 作者认为,对无法行子宫切除的患者,基于内膜活检/刮宫的可靠林奇综合征免疫组化筛查可指导患者管理和遗传咨询。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: Universal screening of endometrial cancer (EC) for Lynch syndrome (LS) has been increasingly implemented in the past five to ten years. Most pathologists initiate screening with immunohistochemistry (IHC) for mismatch repair proteins (MMRPs), using either pre-surgical samplings (endometrial biopsy or curettage, EMB/C) or hysterectomy specimens. We report a systematic assessment of the equivalence of IHC for LS screening on EMB/C versus hysterectomy specimens. METHODS: We identified 99 patients diagnosed with endometrioid EC and performed IHC for MMRPs MLH1, MSH2, MSH6, and PMS2 on their diagnostic EMB/C and paired hysterectomy specimen. Each specimen was scored as MMRP-retained or MMRP-deficient. RESULTS: Ninety-one EMB/Cs had carcinoma, while 8 EMB/Cs showed only complex atypical hyperplasia (CAH). Carcinoma was identified in all 99 hysterectomy specimens. Considering all 99 patients tested, concordance of MMRP expression pattern between EMB/C and paired hysterectomy specimen was 100%. Sixty-nine cases retained all four MMRPs, while 30 were MMRP deficient (26 MLH1- and PMS2-deficient, 3 MSH2- and MSH6-deficient, 1 PMS2-deficient). CONCLUSIONS: In screening for LS in EC, IHC for MMRPs can be performed with identical accuracy on either EMB/C or hysterectomy specimens. Routine testing of diagnostic EMB/Cs may lead to earlier detection of MMRP deficiency, with improved patient uptake of genetic counseling and potential for earlier identification of immunotherapy candidates. Furthermore, reliable IHC-based LS screening performed on EMB/C can guide patient management and genetic counseling in patients unable to undergo hysterectomy.
引用
- Chapel DB, Yamada SD, Cowan M, et al. Immunohistochemistry for mismatch repair protein deficiency in endometrioid endometrial carcinoma yields equivalent results when performed on endometrial biopsy/curettage or hysterectomy specimens. Gynecol Oncol. 2018. PMID: 29656794. doi:10.1016/j.ygyno.2018.04.005
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。